PRA Health Sciences, Inc.

DUBLIN--( BUSINESS WIRE )--The "Clinical Trial Management Systems (CTMS) - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Clinical Trial Management Systems (CTMS) is estimated at US$1.7 Billion in 2023 and is projected to reach US$4.5 Billion by 2030, growing at a CAGR of 14.5% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The growth in the Clinical Trial Management Systems market is driven by several factors. The increasing number of clinical trials, fueled by the rising prevalence of chronic diseases and the urgent need for new therapies, has created a robust demand for efficient trial management solutions. The pharmaceutical and biotechnology industries are heavily investing in research and development, further propelling the need for advanced CTMS platforms. Regulatory requirements and the need for compliance with standards such as Good Clinical Practice (GCP) and the International Council for Harmonisation (ICH) guidelines are also significant drivers, as CTMS helps in maintaining rigorous documentation and reporting standards. Additionally, the shift towards patient-centric trials and personalized medicine is pushing the demand for more adaptive and flexible CTMS solutions that can cater to diverse and dynamic trial designs. The growing adoption of cloud-based CTMS is another critical factor, offering enhanced scalability, reduced IT costs, and improved accessibility. These drivers collectively underscore the essential role of CTMS in optimizing clinical trial processes, ensuring regulatory compliance, and ultimately accelerating the delivery of new treatments to the market. Key Insights: Market Growth: Understand the significant growth trajectory of the Enterprise-Wide CTMS segment, which is expected to reach US$3.1 Billion by 2030 with a CAGR of a 15.0%. The On-Site CTMS segment is also set to grow at 13.4% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, estimated at $477.9 Million in 2023, and China, forecasted to grow at an impressive 13.7% CAGR to reach $684.9 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of major players such as ArisGlobal LLC, BioClinica Inc., Bio-Optronics Inc., and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Attributes: Report Attribute Details No. of Pages 208 Forecast Period 2023 - 2030 Estimated Market Value (USD) in 2023 $1.7 Billion Forecasted Market Value (USD) by 2030 $4.5 Billion Compound Annual Growth Rate 14.5% Regions Covered Global MARKET OVERVIEW Influencer Market Insights Global Economic Update Clinical Trial Management Systems (CTMS) - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Digital Transformation in Healthcare Spurs Adoption of CTMS Solutions Advances in Cloud Computing Expand Addressable Market Opportunity Increased Clinical Trial Complexity Strengthens Business Case for CTMS The Rise of Decentralized Trials Propels Growth of CTMS Market Integration of AI and Machine Learning Technologies Generates New Opportunities for CTMS Adoption of eClinical Solutions Drives Market Expansion Focus on Patient-Centric Trials Accelerates Demand for CTMS Growing Outsourcing of Clinical Trials to CROs Fuels CTMS Market Growth Increased Investment in Life Sciences Sector Drives Adoption of CTMS Interoperability Challenges and Solutions Generate Demand for CTMS The Push for Real-World Evidence (RWE) Strengthens Business Case for CTMS Rising Number of Clinical Trials Globally Expands Addressable Market Opportunity Technological Innovations in CTMS Platforms Propel Market Growth Growth in Biopharmaceutical and Medical Device R&D Generates Demand for CTMS Efforts to Improve Trial Efficiency and Reduce Costs Drive CTMS Market Adoption of Mobile and Remote Monitoring Technologies Spurs Demand for CTMS FOCUS ON SELECT PLAYERS (Total 71 Featured) ArisGlobal LLC BioClinica Inc. Bio-Optronics Inc. DSG Inc. eResearch Technology Inc. IBM Watson Health Medidata Solutions MedNet Solutions Nextrials Inc. Oracle Corp. PAREXEL International Corp. Trial By Fire Solutions LLC Veeva Systems Inc. For more information about this report visit https://www.researchandmarkets.com/r/1ubgyj About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Serial entrepreneur and precision medicine technologist to drive strategic agenda at BC PlatformsZURICH, July 03, 2024 (GLOBE NEWSWIRE) -- BC Platforms, a global leader in real world data, healthcare data management, and analytics, today announces the appointment of a new Chairman of the Board. Alex is a seasoned executive with deep experience at the intersection of healthcare, life sciences, and information technology. He currently sits on the boards of two California-based companies he co-founded: Ryght (applying generative AI to clinical trials) and Chromacode (a cloud-based molecular diagnostics company). Alex also sits on the board of Gencove, an NGS analytics software platform provider based in New York. From 2017 to its acquisition in 2021 for $12B, Alex sat on the board of PRA Health Sciences, a 20,000-employee NASDAQ-listed Clinical Research Organization (CRO) that operated in over 80 countries. From 2010 to 2017, Alex was SVP Strategic Initiatives at Illumina where he led the company’s nation-scale precision medicine program and its cloud computing efforts, developing one of the world’s most widely used bioinformatics platforms, BaseSpace. Alex came to Illumina through its acquisition of Helixis, a life sciences instrument company that he co-founded in 2007 and led as CEO. From 2001 to 2007 he co-founded, and was CEO of, Luxtera, a leading silicon photonics company that was later acquired by Cisco Systems for $660M. Originally from Adelaide, Australia, Alex has a PhD in Electrical Engineering from the University of Adelaide, and an MBA from the Columbia Business School in New York. BC Platforms’ new Chairman of the Board, Alex Dickinson, said, “I’m looking forward to driving BC Platforms’ strategic agenda, working with the remarkable team of industry visionaries committed to making the company a global leader, and trusted partner, in life sciences and healthcare. BC Platforms' unique combination of a federated data network and support for multimodal data types makes it the ideal platform to enable insights from health data and the rapidly growing applications from training data sets for AI-driven drug development to integration of multiomic data into clinical workflows. BC Platforms’ proven technology enables faster and more cost-effective drug development and precision matching of treatments to patient needs.” "Alex’s deep experience in M&A and his track record as a precision medicine evangelist will reinforce and accelerate BC Platforms’ strategy as a global technology enabler for real world data,” said Laurent Samama who has been acting Chairman of the Board. Notes to Editors About BC Platforms BC Platforms provides its international life sciences and healthcare clients with tools, enabling valuable insights across the entire spectrum of research and development, from target identification to fulfilling post-marketing requirements. As a real world data (RWD) solutions company, powered by its leading technology platform, the company is on a mission to deliver personalized medicines using RWD and analytics. The company’s acquisitions of Medexprim, in December 2023, and 4Pharma Ltd, in June 2023, have significantly expanded its ability to provide global biopharma partners with fast and secure access to real world clinical and imaging data assets across Europe, as well as new clinical research services for accelerating the translation of innovations into clinical practice. Taken together, these capabilities provide its customers with actionable insights to advance precision healthcare and conduct research and development more efficiently, thereby helping patients receive better treatments and care. With our innovative technology we are creating a patient-centric infinity loop between the life sciences and healthcare sectors. Data we generate, harmonize, and manage, from diverse biobanks and healthcare institutions, is made accessible for pharmaceutical and biotech companies to enhance their core strengths in research and development. In parallel, we enable stratification of patients towards targeted therapies, delivering on the promise of more personalized healthcare. Founded in 1997 from a MIT Whitehead project spinoff, we have a strong scientific heritage underpinned by over 25 years of working in close collaboration with a network of leading researchers, developers, and industry partners. We have global operations with our headquarters in Zurich, Switzerland, R&D in Espoo, Finland, and Singapore, as well as a presence in London, UK, Lund, Sweden, Toulouse, France and Boston, USA. For more information, visit our website and follow us on LinkedIn. Media Contacts BC Platforms AG: Mikaela Bruhammar – Interim CEOBC Platforms AGmikaela.bruhammar@bcplatforms.com Scius Communications: Katja StoutTel: +44 7789 435 990katja@sciuscommunications.com Daniel GoochTel: +44 7747 875 479daniel@sciuscommunications.com

Strategic Leadership Appointments to Propel Global Growth RALEIGH, N.C., April 11, 2024 /PRNewswire/ -- ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry and a portfolio company of Odyssey Investment Partners is pleased to announce that it has welcomed Kirk Wroblewski as its new Chief Information Officer (CIO) and Andrew Shaw as General Counsel. In addition, ProPharma has promoted Zosya Popik to Chief Marketing Officer (CMO), previously the Vice President of Global Marketing. Continue Reading "We are thrilled to welcome Kirk and Andrew to the executive team and to elevate Zosya as our new Chief Marketing Officer," said Mike Stomberg, Chief Executive Officer. "The combined expertise of each of these team members positions ProPharma to transcend in the industry and continue to compete on a global scale." ProPharma Announces Changes to Its Executive Leadership Team to Propel Global Growth Post this Wroblewski is a highly accomplished, solutions-focused information executive with more than 20 years of experience in healthcare data and analytics. He recently served as the Chief Data Officer for Healthfirst, where he helped build out the near-term and future technical roadmap to match the business goals at the heart of the problems in healthcare. In addition, he held leadership roles at Rainfall Health, Deloitte Digital, Merz Pharma, LabCorp and GSK. "ProPharma helps companies advance at every stage of the pharmaceutical lifecycle and is truly an industry leader," said Wroblewski. "As the new CIO, I'm ready to use my data and analytics expertise to ensure that the staff and technologies within ProPharma's IT department deliver outcomes that support the mission of the business." Popik brings more than 16 years of diverse marketing experience across Fortune 300 companies, fast-moving startups, and the CPG and life sciences industry to her role at ProPharma. She recently led ProPharma's rebranding and repositioning initiative. Prior to joining ProPharma, Zosya held leadership roles across Fortune 300 companies where she built and scaled digital marketing teams from the ground up and spearheaded social media & digital efforts for Icon plc (formerly PRA Health Sciences). She will continue to oversee strategic performance marketing, branding, marketing tech stack, and global communications. "The opportunity to lead and integrate my experiences in digital transformation, global branding, and digital growth at such a pivotal time for ProPharma is both an honor and a challenge I eagerly embrace," said Popik. "In my new position as CMO, I look forward to continue advancing ProPharma's role as the world's largest research consulting organization (RCO)." Shaw serves as General Counsel of ProPharma, where he oversees the global legal function. He has more than 20 years of Life Science experience from both private practice and as in-house counsel. Before joining ProPharma, Shaw led the global legal team at Perspectum Ltd, a UK-based medical device company. He also held senior leadership positions within the legal departments at Fortrea and Syneos Health. Prior to that, he spent eight years in private practice, where he specialized in complex commercial contracting, private equity M&A, and public company transactions. "It's an honor to join a company at the forefront of life sciences, committed to pioneering research and development that advances global health," said Shaw. "I look forward to providing legal and operational excellence to support ProPharma as it continues to deliver impactful healthcare solutions and innovations to the industry." About ProPharma For the past 20 years, ProPharma has improved the health and wellness of patients by providing advice and expertise that empowers biotech, med device, and pharmaceutical organizations of all sizes to confidently advance scientific breakthroughs and introduce new therapies. As the world's largest RCO (Research Consulting Organization), ProPharma partners with its clients through an advise-build-operate model across the complete product lifecycle. With deep domain expertise in regulatory sciences, clinical research solutions, quality and compliance, pharmacovigilance, medical information, and R&D technology, ProPharma offers an end-to-end suite of fully customizable consulting solutions that de-risk and accelerate our partners' most high-profile drug and device programs. For more information about ProPharma, please visit: . About Odyssey Investment Partners Odyssey Investment Partners, with offices in New York and Los Angeles, is a leading private equity investment firm with more than a 25-year history of partnering with skilled managers to transform middle-market companies into more efficient and diversified businesses with strong growth profiles. Odyssey makes majority-controlled investments in industries with a long-term positive outlook and favorable secular trends. For further information about Odyssey, please visit:  . SOURCE ProPharma Group Holdings LLC